Literature DB >> 7490240

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

G D Demetri1, A D Elias.   

Abstract

Cytotoxic chemotherapy remains the principal modality of treating advanced or unresectable sarcomas of soft tissue. Certain drugs, such as doxorubicin and ifosfamide, are able to induce clinically useful antitumor effects as single agents, and combination chemotherapy regimens have been tested based upon these results. This article summarizes the results of single agent and combination chemotherapy trials for soft tissue sarcomas.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7490240

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  29 in total

1.  A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Authors:  Christopher W Ryan; Chacon Matias; Mark Agulnik; Antonio Lopez-Pousa; Charles Williams; Dinesh P de Alwis; Christopher Kaiser; Mary Alice Miller; Sabine Ermisch; Robert Ilaria; M L Keohan
Journal:  Invest New Drugs       Date:  2012-04-27       Impact factor: 3.850

2.  Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Authors:  R Chugh; K A Griffith; E J Davis; D G Thomas; J D Zavala; G Metko; B Brockstein; S D Undevia; W M Stadler; S M Schuetze
Journal:  Ann Oncol       Date:  2015-04-09       Impact factor: 32.976

3.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.

Authors:  Xavier García Del Muro; Joan Maurel; Javier Martínez Trufero; Javier Lavernia; Antonio López Pousa; Ramón de Las Peñas; Ricardo Cubedo; José Pablo Berros; Antonio Casado Herráez; Ana de Juan; Javier Martín Broto
Journal:  Invest New Drugs       Date:  2018-03-12       Impact factor: 3.850

5.  Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.

Authors:  B Brockstein; B Samuels; R Humerickhouse; R Arietta; P Fishkin; J Wade; J Sosman; E E Vokes
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 6.  ET-743.

Authors:  Risto S Cvetkovic; David P Figgitt; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Systemic therapy options for unresectable and metastatic chordomas.

Authors:  Silvia Stacchiotti; Paolo Giovanni Casali
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

8.  Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico.

Authors:  Abdel Karim Dip Borunda; Alberto Pimentel Renteria; Miguel Pluma Jiménez; Mario Pérez Martínez; Gloria Martínez Martínez; Samuel Rivera Rivera; Rocío Grajales Álvarez; Yolanda Bautista Aragón; Miguel Quintana Quintana; Juan Alejandro Silva
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 9.  Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma.

Authors:  V H C Bramwell; D Anderson; M L Charette
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas.

Authors:  Paolo Andrea Zucali; Alexia Bertuzzi; Hector Jose Soto Parra; Elisabetta Campagnoli; Vittorio Quagliuolo; Armando Santoro
Journal:  Invest New Drugs       Date:  2007-09-25       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.